PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i5.12186ArticleRevisiting IL-1 Antagonism in Lung Cancer Therapeutics: Lessons from Failure and Pathways to Precision Therapyhttps://artdesignp.com/journal/PAR/9/5/10.26689/par.v9i5.12186FengSitong,XuCong,QiChuang,LiYi,ShenBo2025952025-10-14Despite compelling preclinical and epidemiological evidence (e.g., reduced lung cancer incidence in the CANTOS trial), IL-1β inhibition with canakinumab failed to achieve the expected therapeutic effect in the Phase III clinical trials (CANOPY series) of non-small cell lung cancer (NSCLC). This perspective analyzes the disconnect between mechanistic promise and clinical outcomes. IL-1β drives NSCLC progression by promoting immunosuppression, angiogenesis, and metastasis. However, CANOPY-2 showed no overall survival (OS) benefit, though a trend emerged in patients with an elevated baseline of high-sensitivity C-reactive protein (hs-CRP). Similarly, CANOPY-1 and adjuvant CANOPY-A missed primary endpoints for progression-free survival (PFS) and disease-free survival (DFS), respectively. These failures highlight limitations of IL-1 monotherapy in advanced, immunosuppressive microenvironments and underscore inadequate patient selection. We propose that IL-1 antagonism retains therapeutic potential but requires refined strategies: biomarker-driven enrichment (e.g., inflammation signatures like hs-CRP), rational combinatorial regimens informed by successful multi-target agents (e.g., cadonilimab), and early-stage intervention. Repositioning IL-1 blockers through precision approaches could unlock their value in immuno-oncology.

Wong C, Baum J, Silvestro A, et al., 2020, Inhibition of IL1β by Canakinumab May Be Effective Against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. Cancer Res, 80(24): 5597–5605.

Garon E, Lu S, Goto Y, et al., 2024, Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. J Clin Oncol, 42(2): 180–191.

Malkova A, Gubal A, Petrova A, et al., 2023, Pathogenetic Role and Clinical Significance of Interleukin-1β in Cancer. Immunology, 168(2): 203–216.

Lythgoe M, Prasad V, 2022, Repositioning Canakinumab for Non-Small Cell Lung Cancer—Important Lessons for Drug Repurposing in Oncology. Br J Cancer, 127(5): 785–787.

Yuan B, Clowers M, Velasco W, et al., 2022, Targeting IL-1β as an Immunopreventive and Therapeutic Modality for K-Ras-Mutant Lung Cancer. JCI Insight, 7(11): e157788.

Paz-Ares L, Goto Y, Lim D, et al., 2024, Canakinumab in Combination With Docetaxel Compared With Docetaxel Alone for the Treatment of Advanced Non-Small Cell Lung Cancer Following Platinum-Based Doublet Chemotherapy and Immunotherapy (CANOPY-2): A Multicenter, Randomized, Double-Blind, Phase 3 Trial. Lung Cancer, 189: 107451.

Tengesdal I, Dinarello C, Marchetti C, 2023, NLRP3 and Cancer: Pathogenesis and Therapeutic Opportunities. Pharmacol Ther, 251: 108545.

Jeon W, Guo M, Gavralidis A, et al., 2024, Unlocking Therapeutic Potential: IL-1β as a Target in Non-Small Cell Lung Cancer With Oncogenic Mutations—Prognostic and Predictive Insights. J Clin Oncol, 42(Suppl 16): 8030.

Lythgoe M, Prasad V, 2022, Repositioning Canakinumab for Non-Small Cell Lung Cancer—Important Lessons for Drug Repurposing in Oncology. Br J Cancer, 127(5): 785–787.